Results 11 to 20 of about 34,967 (216)

Mitochondrial mitophagy protection combining rivaroxaban and aspirin in high glucose-exposed human coronary artery endothelial cell. An in vitro study [PDF]

Diabetes & Vascular Disease Research, 2022
Purpose Combination of Rivaroxaban plus Aspirin improved cardiovascular outcome in patients with stable cardiovascular disease. The aim was to determine if Rivaroxaban and acetylsalicylic acid alone or in combination may protect mitochondrial mitophagy ...
Khaoula Zekri-Nechar, José Javier Zamorano-León, Mercedes Cortina-Gredilla, Ana López-de-Andrés, Rodrigo Jiménez-García, Carlos Navarro-Cuellar, Antonio López-Farré, Carlos Hugo Martínez-Martínez   +7 more
doaj   +2 more sources

Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants

Clinical Medicine Insights: Case Reports, 2015
Rivaroxaban is an orally active direct factor Xa inhibitor used to treat venous thromboembolism with approved starting dose of 15 mg twice-daily. We present a case of an accidental overdose in a patient with pulmonary thromboembolism, when the patient ...
Dimitar Sajkov, Alexander Gallus
doaj   +2 more sources

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation

Therapeutics and Clinical Risk Management, 2014
Alexander GG Turpie Department of Medicine, McMaster University, Hamilton, ONT, Canada Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia in the developed world and is associated with a fivefold increase in the risk of stroke ...
Turpie AGG
doaj   +1 more source

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation

Frontiers in Pharmacology, 2021
Rivaroxaban is commonly used for the prophylaxis of venous thromboembolism (VTE) for patients undergoing major orthopedic surgery. Rivaroxaban is primarily eliminated by hepatic CYP450 metabolism and renal excretion.
Rui-juan Xu, Rui-juan Xu, Tao Ling, Hong Tang, Wei-hong Ge, Qing Jiang   +5 more
doaj   +1 more source

Patient Self-Reported Global Satisfaction With Rivaroxaban in Patients With Atrial Fibrillation: A Comparison Between Oral Anticoagulation-Naïve Versus Oral Anticoagulation-Experienced Patients. [PDF]

Clin Cardiol
Comparisons of the levels of and time trends in patient global satisfaction with rivaroxaban in OAC‐naïve and OAC‐experienced AF patients using a 5‐point scale. Our results suggest that OAC‐naïve patients need additional support, reassurance and more intense clinical follow‐up, particularly in the first 6 months after initiation of DOAC therapy ...
Markovic BG, Mihajlovic M, Kocijancic A, Simic J, Marinkovic M, Kovacevic V, Ivanisevic M, Isailovic N, Mujovic N, Pojskic B, Potpara T, GUARDIAN Investigators.   +11 more
europepmc   +2 more sources

Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation

Research and Practice in Thrombosis and Haemostasis, 2021
Peritoneovenous shunts (PVSs) are used to relieve ascites in cirrhosis. Disseminated intervascular coagulation (DIC) is a complication of PVSs requiring immediate PVS removal.
Fabienne Lucas, Michael S. Stecker, Olga Pozdnyakova, Jean M. Connors, Elisabeth M. Battinelli   +4 more
doaj   +1 more source

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin

Research and Practice in Thrombosis and Haemostasis, 2021
Background Rivaroxaban may induce heavy menstrual bleeding. It is unknown if this effect is dose related or if rivaroxaban is associated with more menstrual bleeding than aspirin. Objectives To demonstrate and compare menstrual patterns and actions taken
Kochawan Boonyawat, Anthonie W. A. Lensing, Martin H. Prins, Jan Beyer‐Westendorf, Paolo Prandoni, Ida Martinelli, Saskia Middeldorp, Akos F. Pap, Jeffrey I. Weitz, Mark Crowther   +9 more
doaj   +1 more source

Non‐synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban

Clinical and Translational Science, 2022
Rivaroxaban is an oral anticoagulant that inhibits thrombin and blocks coagulation cascade through directly inactivating factors Xa. Despite rivaroxaban is widely used for prevention and treatment of venous thrombosis, and its common adverse reactions ...
Ming Zhao, Qiang Zhang, Xizi Wang, Qianqian Zhang, Conghui Tian, Rongrong Li, Xiaodong Jia, Mingliang Gu, Liping Yang   +8 more
doaj   +1 more source

Evaluation of Herb–Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes

Frontiers in Pharmacology, 2022
The combination of Salvia miltiorrhiza (Danshen) and rivaroxaban is a promising treatment option in clinical practice in China, but the herb–drug interaction between Danshen and rivaroxaban remains unclear.
Xu Wang, Jingjing Fa, Yuanjin Zhang, Shengbo Huang, Jie Liu, Junqing Gao, Lina Xing, Lina Xing, Zongjun Liu, Zongjun Liu, Xin Wang   +10 more
doaj   +1 more source

Anticoagulant effects of rivaroxaban, prednisone, alone and in combination, in healthy dogs

Journal of Veterinary Internal Medicine, 2022
Background The potential effects of glucocorticoid administration on rivaroxaban's anticoagulant bioactivity in dogs, and an appropriate rivaroxaban dosage regimen for dogs receiving glucocorticoid therapy are unknown. Hypothesis/Objectives The objective
Paige M. Hafner, Andrew J. Mackin, Robert W. Wills, Marjory B. Brooks, John M. Thomason   +4 more
doaj   +1 more source